Publications

Kim de De Keersmaecker:

  • Ribosomal Lesions Promote Oncogenic Mutagenesis.
    Cancer Res. 2019 Jan 15;79(2):320-327
  • Rise of the specialized onco-ribosomes.
    Oncotarget. 2018 Oct 16;9(81):35205-35206
  • VEGFC Antibody Therapy Drives Differentiation of AML.
    Cancer Res. 2018 Oct 15;78(20):5940-5948.

  • The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
    Leukemia. 2019 Feb;33(2):319-332

  • Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Jun;32(6):1358-1369

Jean Donadieu:

  • Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome.
    Blood. 2018 Sep 20;132(12):1318-1331

  • Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.
    Haematologica. 2018 Aug;103(8):1278-1287

  • TP53 mutations: the dawn of Schwachman clones.
    Blood. 2018 Jan 25;131(4):376

Carlo Dufour:

  • Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.
    Br J Haematol. 2019 Jan;184(2):294-298

  • First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.
    Am J Hematol. 2019 Jan;94 (1) :165

  • A Global MicroRNA Profile in Fanconi Anemia: A Pilot Study.
    Metab Syndr Relat Disord. 2019 Feb;17 (1) :53-59

  • Aerobic metabolism dysfunction as one of the links between Fanconi anemia-deficient pathway and the aggressive cell invasion in head and neck cancer cells.
    Oral Oncol. 2018 Dec;87:210-211

  • Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.
    Am J Hematol. 2019 Jan;94 (1) :80-86

  • A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia.
    Br J Haematol. 2018 Sep 11

  • Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.
    Biol Blood Marrow Transplant. 2018 (questo non sono certa sia tuo)

  • Circulating Follicular Helper and Follicular Regulatory T Cells Are Severely Compromised in Human CD40 Deficiency: A Case Report.
    Front Immunol. 2018 Aug 6;9:1761

  • Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
    Br J Haematol. 2018 Oct;183(1):110-118

  • Mesenchymal stromal cells from Shwachman-Diamond syndrome patients fail to recreate a bone marrow niche in vivo and exhibit impaired angiogenesis.
    Br J Haematol. 2018 Jul;182(1):114-124

  • Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation.
    Bone Marrow Transplant. 2018 Dec;53(12):1548-1552

  • Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil.
    Am J Hematol. 2018 Jul;93(7):E175-E177

  • Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
    Blood. 2018 Apr 26;131(17):1989-1992

  • Altered lipid metabolism could drive the bone marrow failure in fanconi anaemia.
    Br J Haematol. 2019 Feb;184(4):693-696

  • First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.
    Am J Hematol. 2018 May;93(5):643-648

  • Fanconi anemia: from DNA repair to metabolism.
    Eur J Hum Genet. 2018 Apr;26(4):475-476

  • Pearson syndrome.
    Expert Rev Hematol. 2018 Mar;11(3):239-246

Francesca Fioredda:

  • Idiopathic neutropenia of infancy: Data from the Italian Neutropenia Registry.
    Am J Hematol. 2019 Feb;94(2):216-222

  • Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
    Br J Haematol. 2018 Oct;183(1):110-118

  • Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil.
    Am J Hematol. 2018 Jul;93(7):E175-E177

  • Clinical features and therapeutic challenges of cytopenias belonging to alps and alps-related (ARS) phenotype.
    Br J Haematol. 2019 Mar;184(5):861-864

Cristina Mecucci:

  • Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
    Blood. 2018 May 31;131(22):2454-2465

  • Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
    Eur J Haematol. 2018 Jul;101(1):78-85

  • High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
    Leukemia. 2018 Aug;32(8):1807-1810

  • Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin.
    Mol Cytogenet. 2018 Jan 16;11:6

Jan Palmblad:

  • Ethnic benign neutropenia: A phenomenon finds an explanation.
    Pediatr Blood Cancer. 2018 Dec;65(12): e27361

Helen Papadaki:

  • Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
    Leuk Lymphoma. 2018 Nov 14:1-10

  • The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
    Hematol Oncol. 2018 Oct;36(4):693-700

  • Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species.
    Nat Commun. 2018 Aug 20;9(1):3333

  • Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group.
    Leuk Res. 2018 Aug;71:55-59

  • Interactions among myeloid regulatory cells in cancer.
    Cancer Immunol Immunother. 2018 Jul 12

  • Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells.
    Leuk Lymphoma. 2018 Jul 3:1-3

  • Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.
    Blood. 2018 Aug 9;132(6):666-670

  • Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis.
    Hematol Oncol. 2018 Oct;36(4):645-650

  • The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
    Am J Hematol. 2018 Jul;93(7):895-901